Seminars in Oncology
Volume 34, Issue 2 , Pages 154-164 , April 2007

New Molecular Targets and Novel Agents in the Treatment of Advanced Urothelial Cancer

References 

  1. Sternberg CN, Yagoda A, Scher HI, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol. 1985;133:403–407
  2. Loehrer PJ, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol. 1992;10:1066–1073
  3. Sternberg CN, Yagoda A, Scher HI, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium (Efficacy and patterns of response and relapse). Cancer. 1989;64:2448–2458
  4. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068–3077
  5. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602–4608
  6. Adamo V, Magno C, Spitaleri G, et al. Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: Long-term follow-up of a 3-week regimen. Oncology. 2005;69:391–398
  7. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17:3173–3181
  8. Berns A. Cancer genetics (Is p53 the only real tumor suppressor gene?). Curr Biol. 1994;4:137–139
  9. Lorenzo-Romero JG, Salinas-Sanchez AS, Gimenez-Bachs JM, et al. Prognostic implications of p53 gene mutations in bladder tumors. J Urol. 2003;169:492–499
  10. Kuczyk MA, Bokemeyer C, Serth J, et al. p53 overexpression as a prognostic factor for advanced stage bladder cancer. Eur J Cancer. 1995;31A:2243–2247
  11. Shariat SF, Tokunaga H, Zhou J, et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004;22:1014–1024
  12. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66
  13. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645–652
  14. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science. 1985;229:974–976
  15. Jimenez RE, Hussain M, Bianco FJ, et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res. 2001;7:2440–2447
  16. Tetu B, Fradet Y, Allard P, et al. Prevalence and clinical significance of HER/2neu, p53 and Rb expression in primary superficial bladder cancer. J Urol. 1996;155:1784–1788
  17. Lee SE, Chow NH, Chi YC, et al. Expression of c-erbB-2 protein in normal and neoplastic urothelium: Lack of adverse prognostic effect in human urinary bladder cancer. Anticancer Res. 1994;14:1317–1324
  18. Underwood M, Bartlett J, Reeves J, et al. C-erbB-2 gene amplification: A molecular marker in recurrent bladder tumors?. Cancer Res. 1995;55:2422–2430
  19. Lonn U, Lonn S, Friberg S, et al. Prognostic value of amplification of c-erb-B2 in bladder carcinoma. Clin Cancer Res. 1995;1:1189–1194
  20. Vollmer RT, Humphrey PA, Swanson PE, et al. Invasion of the bladder by transitional cell carcinoma: Its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2. Cancer. 1998;82:715–723
  21. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639–2648
  22. Hussain M, Petrylak D, Dunn R, et al. Trastuzumab (T), paclitaxel (P), carboplatin (C), and gemcitabine (G) in advanced HER2-positive urothelial carcinoma: Results of a multi-center phase II NCI trial. J Clin Oncol. 2005;23(suppl 16):379s;(abstr 4507)
  23. Hainsworth JD, Meluch AA, Litchy S, et al. Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer. 2005;103:2298–2303
  24. Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005;23:3706–3712
  25. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  26. Lee JJ, Feng L. Randomized phase II designs in cancer clinical trials: Current status and future directions. J Clin Oncol. 2005;23:4450–4457
  27. Chow NH, Liu HS, Lee EI, et al. Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res. 1997;17:1293–1296
  28. Nguyen PL, Swanson PE, Jaszcz W, et al. Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder (A multivariate survival analysis). Am J Clin Pathol. 1994;101:166–176
  29. Neal DE, Marsh C, Bennett MK, et al. Epidermal-growth-factor receptors in human bladder cancer: Comparison of invasive and superficial tumours. Lancet. 1985;1:366–368
  30. Neal DE, Sharples L, Smith K, et al. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer. 1990;65:1619–1625
  31. Messing EM. Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res. 1990;50:2530–2537
  32. Bue P, Wester K, Sjostrom A, et al. Expression of epidermal growth factor receptor in urinary bladder cancer metastases. Int J Cancer. 1998;76:189–193
  33. Dominguez-Escrig JL, Kelly JD, Neal DE, et al. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin Cancer Res. 2004;10:4874–4884
  34. Petrylak D, Faulkner JR, Van Veldhuizen PJ, et al. Evaluation of ZD1839 for advanced transitional cell carcinoma (TCC) of the urothelium: A Southwest Oncology Group trial. Proc Am Soc Clin Oncol. 2003;22:403;(abstr 1619)
  35. Phillips G, Halabi S, Sanford D, et al. Phase II trial of cisplatin, fixed-dose gemcitabine and gefitinib for advanced transitional cell carninoma of the urothelial tract: Preliminary results from CALGB 90102. J Clin Oncol. 2004;22(suppl 14):4540
  36. Goddard JC, Sutton CD, Furness PN, et al. Microvessel density at presentation predicts subsequent muscle invasion in superficial bladder cancer. Clin Cancer Res. 2003;9:2583–2586
  37. Jaeger TM, Weidner N, Chew K, et al. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol. 1995;154:69–71
  38. Canoglu A, Gogus C, Beduk Y, et al. Microvessel density as a prognostic marker in bladder carcinoma: Correlation with tumor grade, stage and prognosis. Int Urol Nephrol. 2004;36:401–405
  39. Ferara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat. 1995;36:127–137
  40. Izawa JI, Slaton JW, Kedar D, et al. Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. Oncol Rep. 2001;8:9–15
  41. Yang CC, Chu KC, Yeh WM. The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urol Oncol. 2004;22:1–6
  42. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4–25
  43. Crew JP, O’Brien T, Bradburn M, et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res. 1997;57:5281–5285
  44. Bernardini S, Fauconnet S, Chabannes E, et al. Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J Urol. 2001;166:1275–1279
  45. Wu W, Shu X, Hovsepyan H, et al. VEGF receptor expression and signaling in human bladder tumors. Oncogene. 2003;22:3361–3370
  46. Inoue K, Slaton JW, Davis DW, et al. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin Cancer Res. 2000;6:2635–2643
  47. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24:25–35
  48. Rosen L, Mulay M, Long J, et al. Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors. J Clin Oncol. 2003;22:191;(abstr 765)
  49. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16–24
  50. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688–696
  51. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma (Groupe Francais d’Immunotherapie). N Engl J Med. 1998;338:1272–1278
  52. Demetri G, van Oosterom A, Blackstein M, et al. Phase 3, mulitcenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients following failure of imatinib for metastatic GIST. J Clin Oncol. 2005;23:308s;(abstr 4000)
  53. Ratain M, Eisen T, Stadler W, et al. Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol. 2005;23:388s;(abstr 4544)
  54. Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma. J Clin Oncol. 2005;23:380s;(abstr LBA4510)
  55. Fero ML, Randel E, Gurley KE, et al. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature. 1998;396:177–180
  56. Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997;3:231–234
  57. Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res. 2002;8:2505–2511
  58. Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 2004;22:2108–2121
  59. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002;20:4420–4427
  60. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–2498
  61. Sridhar SS, Stadler W, Le L, et al. Phase II study of bortezomib in advanced or metastatic urothelial cancer (A trial of the Princess Margaret Hospital [PMH] Phase II Consortium). J Clin Oncol. 2005;23(suppl 16):422s;(abstr 4677)
  62. Kamat AM, Karashima T, Davis DW, et al. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther. 2004;3:279–290
  63. Wade PA, Gegonne A, Jones PL, et al. Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat Genet. 1999;23:62–66
  64. Solit DB, Zheng FF, Drobnjak M, et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res. 2002;8:986–993
  65. Finnin MS, Donigian JR, Cohen A, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature. 1999;401:188–193
  66. Richon VM, Sandhoff TW, Rifkind RA, et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A. 2002;97:10014–10019
  67. Canes D, Chiang GJ, Billmeyer BR, et al. Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activity in vitro and in vivo. Int J Cancer. 2005;113:841–848
  68. Kelly WK, O’Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005;23:3923–3931
  69. Kelly WK, Richon VM, O’Connor O, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res. 2003;9:3578–3588
  70. Siefker-Radtke AO, Millikan RE, Tu SM, et al. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol. 2002;20:1361–1367
  71. Logothetis CJ, Hossan E, Recondo G, et al. 5-Fluorouracil and interferon-alpha in chemotherapy refractory bladder carcinoma: An effective regimen. Anticancer Res. 1994;14:1265–1269
  72. Kosmidis PA, Bacoyiannis C, Fountzilas G, et al. Hellenic Co-operative Oncology Group 5-Fluorouracil, interferon-alpha-2b and cisplatin (FAP) for advanced urothelial cancer (A phase II study). Ann Oncol. 1997;8:373–378
  73. Zhao R, Babani S, Gao F, et al. The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate. Clin Cancer Res. 2000;6:3687–3695
  74. McDonald AC, Vasey PA, Adams L, et al. A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin Cancer Res. 1998;4:605–610
  75. Rinaldi DA, Burris HA, Dorr FA, et al. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol. 1995;13:2842–2850
  76. Rinaldi DA, Kuhn JG, Burris HA, et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol. 1999;44:372–380
  77. Sweeney CJ, Roth DS, Kaufman SJ. Phase II study of pemetrexed (PEM) for second-line treatment of transitional cell cancer (TCC) of the bladder. Proc Am Soc Clin Oncol. 2003;22:411;(abstr 1653)
  78. von der Maase H, Lehmann J, Gravis G, et al. A phase II trial of pemetrexed plus gemcitabine as first-line treatment for locally advanced or metastatic transitional cell carcinoma of the urothelium. J Clin Oncol. 2005;23(suppl 16):400s;(abstr 4592)
  79. Martinez-Pineiro JA, Gonzalez Martin M, Arocena F, et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: A prospective randomized phase III study. J Urol. 1995;153:964–973
  80. Soloway MS, Einstein A, Corder MP, et al. A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer (A National Bladder Cancer Collaborative Group A Study). Cancer. 1983;52:767–772
  81. Hillcoat BL, Raghavan D, Matthews J, et al. A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. J Clin Oncol. 1989;7:706–709
  82. Reardon JT, Vaisman A, Chaney SG, et al. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum (IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res. 1999;59:3968–3971
  83. Mellish KJ, Kelland LR, Harrap KR. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br J Cancer. 1993;68:240–250
  84. McKeage MJ, Raynaud F, Ward J, et al. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol. 1997;15:2691–2700
  85. Beale P, Raynaud F, Hanwell J, et al. Phase I study of oral JM216 given twice daily. Cancer Chemother Pharmacol. 1998;42:142–148
  86. Sessa C, Minoia C, Ronchi A, et al. Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days. Ann Oncol. 1998;9:1315–1322
  87. Amorino GP, Freeman ML, Carbone DP, et al. Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition. Int J Radiat Oncol Biol Phys. 1999;44:399–405
  88. McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997;15:1853–1857
  89. de Wit R, Kruit WH, Stoter G, et al. Docetaxel (Taxotere): An active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients. Br J Cancer. 1998;78:1342–1345
  90. Roth BJ, Dreicer R, Einhorn LH, et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 1994;12:2264–2270
  91. Dreicer R, Gustin DM, See WA, et al. Paclitaxel in advanced urothelial carcinoma: Its role in patients with renal insufficiency and as salvage therapy. J Urol. 1996;156:1606–1608
  92. Meluch AA, Greco FA, Burris HA, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: A phase II trial of the Minnie pearl cancer research network. J Clin Oncol. 2001;19:3018–3024
  93. Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995;55:2325–2333
  94. Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol). J Biol Chem. 1997;272:2534–2541
  95. Goodin S, Kane MP, Rubin EH. Epothilones: Mechanism of action and biologic activity. J Clin Oncol. 2004;22:2015–2025
  96. Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 2001;7:1429–1437
  97. Spriggs DR, Soignet S, Bienvenu B, et al. Phase I first-in-man study of the epothilone B analog BMS-247550 in patients with advanced cancer. Proc Am Soc Clin Oncol. 2001;20:108;(abstr 428)
  98. Mani S, McDaid H, Shen H, et al. Phase I pharmacokinetic and pharmacodynamic study of an epothilone B analog (BMS-247550) administered as a 1-hour infusion every 3 weeks: An update. J Clin Oncol. 2002;21:103a;(abstr 409)
  99. Tripathi R, Gadgeel SM, Wozniak AJ, et al. Phase I clinical trial of BMS-247550 (epothilone B derivative) in adult patients with advanced solid tumors. J Clin Oncol. 2002;21:102a;(abstr 407)
  100. Awada A, Bleiberg H, de Valeriola D, et al. Phase I clinical and pharmacology study of the epothilone analog BMS-247550 given weekly in patients (Pts) with advanced solid tumors. J Clin Oncol. 2001;21:108a;(abstr 427)
  101. Hao D, Hammond LA, deBono JS, et al. Continuous weekly administration of the epothilone-B derivative, BMS247,550 (NSC710428): A phase I and pharmacokinetic (PK) study. J Clin Oncol. 2002;2:103a;(abstr 411)
  102. Burris HA, Awada A, Jones S, et al. Phase I study of the novel epothilone BMS-247550 administered weekly in patients (pts) with advanced malignancies. J Clin Oncol. 2002;21:104a;(abstr 412)
  103. Thambi PM, Edgerly M, Agrawal M, et al. A phase I clinical trial of BMS-247550 (NSC 71028), an epothilone B derivative, given daily for 3 days on a 21 day cycle in patients with refactory neoplasms. Proc Am Soc Clin Oncol. 2003;22:135;(abstr 540)
  104. Abraham J, Agrawal M, Bakke S, et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol. 2003;21:1866–1873
  105. Ngan VK, Bellman K, Panda D, et al. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res. 2000;60:5045–5051
  106. Kruczynski A, Barret JM, Etievant C, et al. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated vinca alkaloid. Biochem Pharmacol. 1998;55:635–648
  107. Hill BT, Fiebig HH, Waud WR, et al. Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur J Cancer. 1999;35:512–520
  108. Lobert S, Ingram JW, Hill BT, et al. A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity. Mol Pharmacol. 1998;53:908–915
  109. Johnson P, Geldart T, Fumoleau P, et al. Phase I study of Vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks. Invest New Drugs. 2006;24:223–231
  110. Bennouna J, Fumoleau P, Armand JP, et al. Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol. 2003;14:630–637
  111. Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005;4:1086–1095
  112. Towle MJ, Salvato KA, Budrow J, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001;61:1013–1021

PII: S0093-7754(06)00484-2

doi: 10.1053/j.seminoncol.2006.12.007

Seminars in Oncology
Volume 34, Issue 2 , Pages 154-164 , April 2007

Article Tools

* Image Usage & Resolution